Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nicardipine Hydrochloride Capsules is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible.
Product Name : Nicardipine Hydrochloride-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, is the generic version of Cardene®1 Capsules, 20 mg and 30 mg, of Chiesi USA, Inc. Nicardipine Hydrochloride capsules, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.
Product Name : Nicardipine Hydrochloride-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicardipine Hydrochloride,Emu oil,Superoxide Dismutase
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : H-100 (nicardipine), a novel, patented, non-invasive topical treatment being developed for Peyronie’s disease, is being developed as a topical gel using nanotechnology to potentially enhance permeation of the medication.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 03, 2022
Lead Product(s) : Nicardipine Hydrochloride,Emu oil,Superoxide Dismutase
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicardipine Hydrochloride,Emu oil,Superoxide Dismutase
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Hybrid Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : H-100 may be able to provide the first-ever non-invasive treatment to a confounding and often painful condition for which there have been few viable solutions. As a topical, H-100 has the potential to be approved as the first non-invasive treatment for t...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 08, 2021
Lead Product(s) : Nicardipine Hydrochloride,Emu oil,Superoxide Dismutase
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Hybrid Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : NeuroScios | Data Magik | pharm-analyt Labor
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nicardipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Subarachnoid Hemorrhage.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 13, 2020
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : NeuroScios | Data Magik | pharm-analyt Labor
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Yale University | Thomas Jefferson University | University of Illinois, Chicago | Wake Forest University Health Sciences | Temple University | Geisinger Clinic | Northwell Health | University of Michigan | Lenox Hill Hospital | Weatherhead Foundation | Un
Deal Size : Inapplicable
Deal Type : Inapplicable
The Intra-arterial Vasospasm Trial
Details : Nicardipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Vasospasm, Intracranial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 27, 2013
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Yale University | Thomas Jefferson University | University of Illinois, Chicago | Wake Forest University Health Sciences | Temple University | Geisinger Clinic | Northwell Health | University of Michigan | Lenox Hill Hospital | Weatherhead Foundation | Un
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Perdipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 07, 2013
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
